Connect with us

Politics

DEA Head Slammed Over Marijuana Stance By Lawmakers

Published

on

The acting administrator of the Drug Enforcement Administration (DEA) was put through the wringer by lawmakers on Capitol Hill on Tuesday, pressed repeatedly to answer questions about the federal agency’s outdated marijuana policy.

Here’s a roundup of exchanges between DEA Acting Administrator Robert Patterson and members of the House Judiciary Committee during a hearing on the opioid epidemic.

Rep. Steve Cohen (D-TN) 

“The DEA has always been in a position of great importance—and it’s important that the DEA administrator stay current with what the people have shown by their actions and their statements what they believe is the right priorities for the DEA,” Cohen started.

In short, the people don’t think marijuana should be a federal law enforcement priority, he said. He then asked Patterson why marijuana is classified in the same drug scheduling category as more harmful drugs such as heroin.

“The reason why it remains in Schedule I is the science,” Patterson said.

“The science?” Cohen responded. He later added, “I’m happy to hear that you believe in science, that’s refreshing.” But Cohen wanted to know what the DEA official’s personal views on marijuana scheduling were, and Patterson delivered: He said that he was worried the country was “going down a bad path with marijuana” and that all of the national conversations around reform mainly had to do with revenue.

Cohen pushed back, arguing that adults also care about racially disproportionate arrests for non-violent marijuana offenses, for instance. Patterson said he didn’t see a link between prohibitionist marijuana policies and mass incarceration, then went into a rant that concluded:

“At what point did we determine that revenue was more important than our kids?”

Rep. Hank Johnson (D-GA)

Johnson began his questioning by asking Patterson how many Americans died from opioid-related overdoses among the 64,000 drug overdose deaths recorded in 2016.

Patterson knew that figure, responding that about 44,000 deaths were the result of opioid-related overdoses. But when asked a follow-up question about marijuana-related overdose deaths, the DEA official said that he didn’t believe there were any officially recorded in 2016, but that he was “aware of a few deaths from marijuana.”

(The DEA itself said there were no known deaths attributed to a marijuana overdose in a 2017 report on drug abuse.)

“You are aware of a few deaths from marijuana?” Johnson asked. At that point, Patterson said that he didn’t have materials in front of him to reference, but that he believed these deaths were caused by “adulterated” cannabis and said he ultimately understood the congressman’s point: that in terms of risk of overdose, marijuana and opioids are “not comparable.”

Rep. Eric Swalwell (D-CA)

Swalwell used his time at the hearing to talk about the struggles of families he’s met whose children have either fatally overdosed on opioids or suffered from addiction. He asked Patterson what can be done to prevent and address youth substance abuse.

The DEA official discussed the importance of early education drug prevention programs—and then pivoted to marijuana.

“I hate to do this, but I’m going to do it to you—and this is what concerns me about marijuana because those same stories I hear all the time, I generally hear marijuana introduced,” Patterson said. But he then made a surprising admission, telling Swalwell that he’s “not going to compare” drugs like marijuana and opioids, and also that he wouldn’t “say [marijuana is] a gateway [drug].”

That caveat was significant, Don Murphy, director of conservative outreach at the Marijuana Policy Project, said in a statement to Marijuana Moment. “When the head of the DEA rejects the gateway theory, he’s a witness for an end to prohibition,” Murphy said. 

Patterson did go on to say that “the problem is that these things all seem to dovetail together, and my concern is—and again, I’ll take my DEA hat off for a second is as a person in the United States—what message we send as we try to navigate this space in terms of that, and I think that’s problematic.”

Rep. Matt Gaetz (R-FL)

Gaetz wanted to know whether it is “the position of the DEA that democratizing access to medical marijuana will add to the substance abuse problem in this country.” Patterson said he feels “it’s a conversation that we have to have.”

But that question appeared to set Gaetz up for an extensive back-and-forth during which the DEA head demonstrated a stunning lack of knowledge about the existing scientific literature concerning marijuana’s health benefits and its potential use as a substitute for dangerous pharmaceuticals, including opioid painkillers.

Was Patterson familiar with a 2017 report from the National Academies of Science that found “conclusive or substantial evidence” that cannabis and cannabinoids effectively treats chronic pain—a condition that is traditionally treated with opioid painkillers? No.

Was he familiar any of the numerous patient surveys from states where marijuana has been legalized, showing significant reductions in pharmaceutical use correlated with cannabis reform? No.

OK, was he aware of any studies that showed the opposite? That marijuana use was associated with increased use of dangerous illicit drugs? Again, no.

So then, going back to his first question, why is it that the DEA cannot speak to its official position as to whether marijuana legalization would add to the country’s substance abuse problem if its acting administrator can’t defend that argument based on any “evidentiary standpoint,” Gaetz asked. A flustered Patterson reaffirmed the agency’s support for research into medical marijuana and also pinned blame on the lack of DEA-approved research grants for medical marijuana research on international treaties that he claimed were being deliberated by the Justice Department.

Gaetz said he appreciated the agency’s support for research and asked whether the DEA would commit to partnering with lawmakers in their efforts to expand federal marijuana research.

“We’ve been consistent in that message,” Patterson said.

Marijuana Kills People, DEA Claims

Photo courtesy of Ted Eytan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Business

Senate Schedules Hearing On Marijuana Business Banking Access

Published

on

In one of the clearest signs of marijuana reform’s growing momentum on Capitol Hill, a Republican-controlled Senate committee has scheduled a hearing for next week that will examine cannabis businesses’ lack of access to banking services.

The formal discussion in the Senate Committee on Banking, Housing and Urban Affairs on Tuesday comes as legislation aimed at resolving the marijuana industry’s financial services problems is gaining momentum. A House cannabis banking bill that cleared that chamber’s Financial Services Committee with a bipartisan vote in March now has 206 cosponsors—nearly half the body—while companion Senate legislation has 32 out of 100 senators signed on.

Please visit Forbes to read the rest of this piece.

(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Congressman Files Marijuana Bill After Leaving Republican Party

Published

on

In one of his first legislative acts since leaving the Republican Party earlier this month amid a feud with the president, Rep. Justin Amash (I-MI) filed a bill on Monday that would let states set their own marijuana policies without federal interference.

If that sounds familiar, it’s because bipartisan legislation that would accomplish the same goal has already been filed this Congress.

But unlike the nearly identical Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, Amash’s new bill excludes one provision that would require the Government Accountability Office (GAO) to study the effects of cannabis legalization on road safety and issue a report on its findings within a year of the law’s enactment.

That language states that the GAO must study “traffic crashes, fatalities, and injuries” in legal cannabis states, actions taken by those states to “address marihuana-impaired driving,” testing standards being used to detect impaired driving and federal initiatives “aiming to assist States that have legalized marihuana with traffic safety.”

Given Amash’s libertarian leanings, it stands to reason that he opposes spending government dollars to conduct the research and simply supports the broader states’ rights intent of the original legislation.

That would also put him at odds with social justice advocates who feel that the STATES Act itself doesn’t go far enough and are pushing for more comprehensive legislation that includes additional provisions addressing social equity and restorative justice for people harmed by drug law enforcement.

Members of the House Judiciary Crime, Terrorism and Homeland Security Subcommittee heard that debate play out during a historic hearing on ending federal marijuana prohibition last week.

A newly formed coalition of civil rights and drug reform organizations, including the ACLU, is also insisting on passing wide-ranging legislation to deschedule cannabis entirely that also invests in communities that have been disproportionately impacted by prohibition.

Amash is a long-standing critic of the war on drugs and earlier this year signed on as a cosponsor of a separate bill that would federally deschedule marijuana. Rep. Tulsi Gabbard (D-HI), a 2020 Democratic presidential candidate, filed that legislation, which is also silent on social equity provisions.

Gabbard also introduced a separate bill that would require the U.S. Department of Health and Human Services and other federal agencies to study the impacts of legalization. True to form, Amash declined to add his name to that measure as well.

Read the text of Amash’s new cannabis bill below:

AMASH_038_xml by Marijuana Moment on Scribd

Former GOP Congressman Explains Why Broad Marijuana Reform Is Achievable In 2020

Photo courtesy of Kyle Jaeger.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Berkeley City Council Considers Decriminalizing Psychedelics This Week

Published

on

A resolution to decriminalize psilocybin and other psychedelics will go before a Berkeley, California City Council committee on Wednesday.

Decriminalize Nature, the group behind the measure, also led the charge to successfully get a measure decriminalizing entheogenic plants and fungi approved by the City Council in neighboring Oakland last month.

In Berkeley, the Public Safety Committee will discuss the proposal and can either decide to hold it for a future meeting or advance it to the full Council. The public is able to attend Wednesday’s special meeting and share their perspective on the resolution, but Decriminalize Nature stressed in a tweet that this “is a small meeting, so you do NOT need to attend.”

However, city residents are being encouraged to write to their Council members and urge them to vote in favor of the measure, which would codify that “no department, agency, board, commission, officer or employee of the city, including without limitation, Berkeley Police Department personnel, shall use any city funds or resources to assist in the enforcement of laws imposing criminal penalties for the use and possession of Entheogenic Plants by adults of at least 21 years of age.”

The resolution defines the covered substances as “plants and natural sources such as mushrooms, cacti, iboga containing plants and/or extracted combinations of plants similar to ayahuasca; and limited to those containing the following types of compounds: indoleamines, tryptamines, phenethylamines.”

Councilmembers Rigel Robinson and Cheryl Davila are sponsoring the resolution, which does not allow for commercial sales or manufacturing.

The lawmakers provided background information on the measure in a report to their colleagues and the mayor, describing the medical potential of various psychedelics as well as the success of decriminalization measures in Denver and Oakland.

“It is intended that this resolution empowers Berkeley residents to be able to grow their own entheogens, share them with their community, and choose the appropriate setting for their intentions instead of having to rely exclusively on the medical establishment, which is slow to adapt and difficult to navigate for many,” they wrote.

While efforts to eliminate criminal penalties associated with psilocybin and other psychedelics have so far centered in jurisdictions that have historically embraced marijuana legalization and broader drug reform, the conversation around decriminalizing psychedelics is spreading nationally.

Shortly after Oakland approved its measure, Decriminalize Nature received inquiries from activities in cities from across the country. The group has kept track of each city where organizers are pursuing decriminalization.

On Monday, a conversation around changing laws governing psychedelics reared during a City Council meeting in Columbia, Missouri. One resident implored the body to take up a resolution to decriminalize the natural substances, pointing to their therapeutic benefits.

Councilmember Mike Trapp said that the student’s proposal should be considered and that a government advisory board on public health should provide input on the medical potential of psychedelics, describing it as “very promising.”

Hawaii Governor Vetoes Two Cannabis Bills While Letting Decriminalization Become Law

Photo elements courtesy of carlosemmaskype and Apollo.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Stay Up To The Moment

Marijuana News In Your Inbox


Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!